Myokardia, inc. (MYOK)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flow from operating activities:
Net loss

-276,213

-67,698

-57,010

-10,380

-22,946

-16,829

-12,700

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

32,994

19,341

6,138

2,813

516

92

41

Depreciation

1,900

1,600

1,300

1,111

965

712

478

Amortization of discount on investments

1,619

279

-85

-

-

-

-

Loss on disposal of equipment

-

-

-4

-

4

-

-

Redeemable convertible preferred stock call option liability, net issued in connection with license and collaboration agreement

-

-

-

-

-

686

-

Change in fair value of redeemable convertible preferred stock call option liability, net

-

-

-

-

314

387

932

Change in operating assets and liabilities:
Receivable from collaboration partner

-

-1,013

-43,987

45,000

-

-

-

Prepaid expenses and other current assets

2,612

2,884

482

112

852

198

122

Operating lease right-of-use assets

-2,618

-

-

-

-

-

-

Other long-term assets

-290

296

59

24

-39

-

-

Accounts payable

3,064

671

367

-434

1,301

-340

63

Accrued liabilities

11,665

8,945

2,968

3,250

2,940

1,540

378

Prepayment from collaboration partner

12,973

-8,541

-4,432

-

-

-

-

Operating lease liabilities

-2,838

-

-

-

-

-

-

Other long-term liabilities

1,907

-178

-120

-109

454

-16

263

Deferred revenue

-

-33,558

-11,442

28,029

-14,199

28,398

-

Net cash used in operating activities

-241,769

-64,815

-9,838

-20,856

-32,100

13,658

-12,531

Purchases of investments

259,897

132,475

44,044

16,060

-

-

-

Sales of investments

4,000

8,000

4,000

-

-

-

-

Maturities of investments

78,000

28,000

4,000

-

-

-

-

Purchases of property and equipment

3,264

3,373

1,517

1,083

1,446

716

1,169

Proceeds from sale of equipment

-

-

10

-

134

-

-

(Increase) decrease in restricted cash

-

-

-

-

-60

260

-

Net cash provided by (used in) investing activities

-181,161

-99,848

-37,551

-17,143

-1,252

-976

-1,169

Proceeds from issuance of common stock in follow-on offerings, net of issuance and financing costs

271,224

181,863

133,862

61,148

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

318

Proceeds from issuance of common stock during IPO, net of issuance costs

-

-

-

-

55,780

-

-

Proceeds from exercise of stock options and employee stock purchase plan

7,071

6,208

2,365

506

352

165

-

Payments of prior period offering costs

-

-

38

153

-

-

-

Net cash provided by financing activities

278,295

188,071

136,189

61,501

101,969

29,055

10,953

Net increase in cash, cash equivalents and restricted cash

-144,635

23,408

88,800

23,502

68,617

41,737

-2,747

Non-cash investing and financing activities:
Unpaid portion of property and equipment purchases included in period-end accounts payable and accrued liabilities

9,756

468

283

103

61

91

103

Vesting of early exercised options and restricted stock

15

53

184

272

177

104

17

Unpaid financing-related costs included in period-end accounts payable and accrued liabilities

-

-

-

38

153

-

-

Loan issued in connection with restricted stock purchase agreement

-

-

-

-

-

-

38

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

98

158

179

Accretion of dividends on redeemable convertible preferred stock

-

-

-

-

5,151

2,864

1,087